ACCESS Newswire
07 Jun 2023, 15:35 GMT+10
License from Gilead grants AbTherx worldwide rights to a novel human therapeutic antibody discovery platform
MOUNTAIN VIEW and SAN DIEGO, CA / ACCESSWIRE / June 7, 2023 / AbTherx, Inc., a privately held biotech company focused on accelerating the discovery and development of antibody therapeutics, today announced a license agreement with Gilead Sciences, Inc. (NASDAQ:GILD). The license agreement will provide AbTherx rights to Gilead's recently acquired novel transgenic mouse technologies, which were developed by three of the AbTherx founders. AbTherx will commercialize these technologies as Atlas™ Mice.
The licensed technologies enable the development of a clinically validated bispecific antibody format most similar to native antibodies, use natural mechanisms to generate long CDR3 antibodies to improve the chance of success against challenging drug targets such as GPCRs and ion channels, and increase access to transgenic mice expressing full human antibody diversity. AbTherx intends to further develop these technologies and partner with global pharmaceutical and biotechnology companies to deliver innovative medicines. The agreement also provides Gilead with non-exclusive rights to future AbTherx-developed transgenic mouse technologies, which will add to Gilead's existing portfolio of antibody discovery technologies.
'We are honored that Gilead has entrusted AbTherx to further develop and commercialize these technologies for the betterment of human health. Combining this platform with our decades of experience in antibody discovery and developing transgenic mice, AbTherx is uniquely positioned to deliver the next generation of antibody therapeutics,' said Justin Mika, Chief Executive Officer of AbTherx. 'We are extremely proud to partner our expertise with Gilead's renowned drug development capabilities.'
About AbTherx, Inc.
AbTherx, Inc. was founded in 2023 and is advancing medicine with novel technologies that accelerate and enable therapeutic antibody discovery. The company was founded by a leadership team with over 100 years of combined experience in antibody discovery and platform development, including development of the HuMAb Mouse® technology, the most successful human antibody discovery platform with 13 marketed therapeutics. AbTherx's Atlas™ Mouse platform enables the development of a clinically validated bispecific antibody format most similar to native antibodies and uses natural mechanisms to generate long CDR3 antibodies to improve the chance of success against challenging drug targets such as GPCRs and ion channels. AbTherx is also increasing access to transgenic mice expressing full human antibody diversity. Through technology licensing and research collaborations, AbTherx partners with drug developers of all sizes to overcome the most demanding challenges in delivering innovative medicines. For more information, please visit www.abtherx.com.
Media Contact
Stacey Borders
[email protected]
SOURCE: AbTherx, Inc.
Get a daily dose of Albuquerque Express news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Albuquerque Express.
More InformationTORONTO, Canada - Tens of thousands of people from across Canada have marched in support of Israel in a massive turnout in Toronto....
BOSTON, Massachusetts: U.S. President Donald Trump's administration has taken away Harvard University's right to enroll international...
WASHINGTON, DC - U.S. President Donald Trump on Monday said he believed God was behind his election loss in 2020, even though he has...
NEW YORK CITY, New York: Passenger numbers at Newark Liberty International Airport in New Jersey have dropped sharply, according to...
BRUSSELS, Belgium: European Union antitrust regulators are examining fees imposed by payment giants Visa and Mastercard, Bloomberg...
WASHINGTON, D.C.: The U.S. Army plans to change the records of transgender soldiers to list only their sex at birth, according to a...
NEW YORK, New York - Strong economic data jump-started U.S. stocks and the dollar Tuesday, a welcome reprieve after weeks of pressure...
NEW YORK CITY, New York: This week, the U.S. Federal Trade Commission (FTC) dropped its lawsuit against PepsiCo, which had accused...
WASHINGTON, D.C.: New single-family home sales in the U.S. rose sharply in April to their highest level in over three years as builders...
VEVEY, Switzerland: Nestle is realigning its focus on its core food and beverage operations after expanding into areas like health...
DEARBORN, Michigan: Ford Motor Company has filed a lawsuit against several California lawyers and law firms, accusing them of cheating...
BRUSSELS, Belgium: U.S. drugmakers are charging significantly more for new treatments, particularly those targeting rare diseases,...